Corbus Pharma's Positive Phase 2 Study: Safety First
March 30, 2017 at 14:56 PM EDT
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has received a price target increase to $24 from $17 from Cantor Fitzgerald, which ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.